Pfizer and Merck KGaA's plans to jointly develop the latter's anti-PD-L1 drug is positive news for all in the field.
Pfizer and Merck KGaA's plans to jointly develop the latter's anti-PD-L1 drug is positive news for all in the field.
Pfizer and Germany's Merck have entered into a global agreement to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody belonging...
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Series B cash will be used to advance its Stargardt disease gene therapy.
